Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-715-8 | CAS number: 109-88-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2010-04-13 to 2010-04-29
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted according to Guidelines in a GLP certified laboratory.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- Magnesium hydroxide
- EC Number:
- 215-170-3
- EC Name:
- Magnesium hydroxide
- Cas Number:
- 1309-42-8
- Molecular formula:
- H2MgO2
- IUPAC Name:
- magnesium dihydroxide
- Details on test material:
- Identification: Magnesium hydroxide
Molecular formula: Mg(OH)2
Molecular weight: 58.32
CAS Number: 1309-42-8
Stable under storage conditions: Stable
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: 8 weeks approx.
- Weight at study initiation: Body weight variation of selected animals did not exceed +/- 20% of the sex mean
- Fasting period before study: Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test substance. Water was available ad libitum
- Housing: Group housing of 3 animals per cage in labeled Macrolon cages containing sterilised sawdust as bedding material
- Diet: Pelleted rodent diet was available ad libitum
- Water: Ad libitum
- Acclimation period: Not stated
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.8 - 21.5 °C
- Humidity (%): 34 - 60 %
- Photoperiod (hrs dark / hrs light): 12 hours dark and 12 hours light
IN-LIFE DATES: From: 13th April 2010 To: 29th April 2010
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/ml
- Amount of vehicle (if gavage): 10 ml/kg
- Justification for choice of vehicle: Standard vehicle for use in testing
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Limit test - Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 3 female animals per dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for mortaility/viability twice daily. Body weights were measured on day 1 (pre-administration), day 8 and day 15.
- Necropsy of survivors performed: Yes.
- Other examinations performed: Clinical signs were observed at periodic intervals on the day of dosing (day 1) and once daily thereafter, until day 15. The symptoms were graded according to fixed scales and the time of onset, degree and duration were recorded. - Statistics:
- Not required
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No mortality occurred (see Table 1).
- Clinical signs:
- other: Hunched posture and/or piloerection was noted among all animals on Day 1 (see Table 2).
- Other findings:
- Macroscopic findings:
No abnormalities were found at macroscopic post mortem examination of the animals ( see Table 4).
Any other information on results incl. tables
Table 1: Mortality Rate
Test day |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Females 2000 MG/KG |
X |
X |
X |
X |
X |
X
|
X |
X |
X |
X |
X
|
X |
X |
X |
X |
X |
X |
Females 2000 MG/KG |
X
|
X
|
X
|
X
|
X
|
X |
X
|
X |
X
|
X |
X |
X |
X |
X |
X |
X |
X |
Key: X= no signs observed
Table 2: Clinical Signs
Test day |
|
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
Max grade |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Females 2000MG/KG Animal 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture |
(1) |
√ |
√ |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Skin/fur Piloerection |
(1) |
X |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Animal 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture |
(1) |
√ |
√ |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Animal 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture
|
(1) |
√ |
√ |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Females 2000 MG/KG Aniaml 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture |
(1) |
√
|
√ |
√ |
X |
X
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Skin/fur piloerection |
(1) |
X |
√ |
X |
X
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X
|
X |
Animal 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture |
(1) |
√ |
√ |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Skin/fur piloerection
|
(1) |
X |
√ |
X |
X |
X |
X |
X |
X
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
Animal 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture Hunched posture |
(1) |
√ |
√ |
√ |
X |
X |
X |
X |
X |
X
|
X |
X
|
X |
X |
X |
X |
X |
X |
Skin/fur piloerection |
(1) |
X |
√ |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Key: X= no signs observed
√=signs observed
Table 3: Body Weights (Gram)
Sex/Dose |
Animal |
Day 1 |
Day 8 |
Day 15 |
Females 2000 MG/KG |
|
|
|
|
|
1 |
149 |
175 |
189 |
|
2 |
151 |
180 |
192 |
|
3
|
146 |
174 |
189 |
|
Mean |
149 |
176 |
190 |
|
St. Dev |
3 |
3 |
2 |
|
N
|
3 |
3 |
3 |
|
4 |
155 |
179 |
196 |
|
5 |
153 |
174 |
188 |
|
6
|
161 |
185 |
194 |
|
Mean |
156 |
179 |
193 |
|
St.Dev |
4 |
6 |
4 |
|
N |
3 |
3 |
3 |
Table 4: Macroscopic Findings
Animal Organ |
Finding |
Day of Death |
Females 2000 Mg/Kg |
||
1 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
2 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
3 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
Females 2000 Mg/Kg |
||
4 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
5 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
6 |
No Findings Noted |
Scheduled necropsy Day 15 after treatment |
Applicant's summary and conclusion
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: OECD GHS
- Conclusions:
- The oral LD50 value of magnesium hydroxide in Wistar rats was established to exceed 2000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to exceed 5000 mg/kg body weight.
Based on these results, Magnesium hydroxide does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the:
- Globally Harmonised System of Classification and Labelling of Chemicals (GHS) of the United Nations (2007)
-Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures. - Executive summary:
First set of females- dose level = 2000 mg/kg
Second set of females- dose level= 2000 mg/kg
No mortality occurred. Hunched posture and/or piloerection was noted among all animals on Day 1. The mean body weight gain shown by the animals over the study period was considered to be similar to that expected of normal untreated animals of the same age and strain. No abnormalities were found at macroscopic post mortem examination of the animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.